JP2010511729A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511729A5
JP2010511729A5 JP2009540451A JP2009540451A JP2010511729A5 JP 2010511729 A5 JP2010511729 A5 JP 2010511729A5 JP 2009540451 A JP2009540451 A JP 2009540451A JP 2009540451 A JP2009540451 A JP 2009540451A JP 2010511729 A5 JP2010511729 A5 JP 2010511729A5
Authority
JP
Japan
Prior art keywords
item
composition
progestagen
pharmaceutically acceptable
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009540451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511729A (ja
Filing date
Publication date
Priority claimed from US11/634,347 external-priority patent/US20080132475A1/en
Application filed filed Critical
Publication of JP2010511729A publication Critical patent/JP2010511729A/ja
Publication of JP2010511729A5 publication Critical patent/JP2010511729A5/ja
Pending legal-status Critical Current

Links

JP2009540451A 2006-12-05 2007-12-05 ドライアイのための処置 Pending JP2010511729A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/634,347 US20080132475A1 (en) 2006-12-05 2006-12-05 Treatment for dry eye
PCT/US2007/086515 WO2008070726A2 (en) 2006-12-05 2007-12-05 Treatment for dry eye

Publications (2)

Publication Number Publication Date
JP2010511729A JP2010511729A (ja) 2010-04-15
JP2010511729A5 true JP2010511729A5 (https=) 2012-01-05

Family

ID=39476533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009540453A Pending JP2010511730A (ja) 2006-12-05 2007-12-05 テストステロンおよびプロゲスターゲンを用いたドライアイのための処置
JP2009540451A Pending JP2010511729A (ja) 2006-12-05 2007-12-05 ドライアイのための処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009540453A Pending JP2010511730A (ja) 2006-12-05 2007-12-05 テストステロンおよびプロゲスターゲンを用いたドライアイのための処置

Country Status (12)

Country Link
US (3) US20080132475A1 (https=)
EP (2) EP2101785A4 (https=)
JP (2) JP2010511730A (https=)
KR (2) KR20090104813A (https=)
CN (2) CN101636164A (https=)
AU (1) AU2009202711A1 (https=)
BR (2) BRPI0720172A2 (https=)
CA (2) CA2671698A1 (https=)
EA (2) EA200900662A1 (https=)
IL (1) IL199094A0 (https=)
MX (2) MX2009005993A (https=)
WO (2) WO2008070726A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
WO2010016042A1 (en) * 2008-08-05 2010-02-11 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
KR101914940B1 (ko) * 2011-01-26 2018-11-06 알러간, 인코포레이티드 안과 질환을 치료하기 위한 안드로겐 조성물
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
ES2759781T3 (es) * 2012-07-27 2020-05-12 Glia Llc Composiciones y tratamiento para enfermedades y trastornos oculares
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HUE034886T2 (hu) * 2013-03-15 2018-03-28 Glia Llc Gyógyszerek cranialis adagolása
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
EP3848028B9 (en) * 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
HK1243349A1 (en) * 2015-04-03 2018-07-13 Santen Pharmaceutical Co., Ltd. Dry eye therapeutic agent having as active ingredient nandrolone or ester thereof or methenolone or ester thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10098895B2 (en) 2016-09-07 2018-10-16 Glia, Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
TW202131927A (zh) * 2019-11-13 2021-09-01 美商葛莉亞有限責任公司 睾固酮組合物
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS59184135A (ja) * 1983-04-04 1984-10-19 Teijin Ltd グリセリンピログルタミン酸エステル類を含有する医薬品組成物
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
DE3514724A1 (de) * 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
JPH07508716A (ja) * 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
EP1806131A3 (en) * 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
HUP0001748A3 (en) * 1997-02-28 2001-03-28 Minnesota Mining And Mfg Co Sa Transdermal device for the delivery of testosterone
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
FR2774587B1 (fr) * 1998-02-09 2000-03-10 Oreal Utilisation d'une microdispersion de cire dans une composition cosmetique ou dermatologique
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6583129B1 (en) * 1999-06-11 2003-06-24 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
AU1731101A (en) * 1999-12-07 2001-06-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US6630175B1 (en) * 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
WO2002055020A2 (en) * 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
WO2004045510A2 (en) * 2002-11-15 2004-06-03 Panaseca, Inc. Methods and compositions for alleviating dry eyes
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US7960350B2 (en) * 2003-10-24 2011-06-14 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006014484A2 (en) * 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen

Similar Documents

Publication Publication Date Title
JP2010511729A5 (https=)
AU2020203213B2 (en) Pharmaceutical nanoparticles showing improved mucosal transport
JP2010511730A5 (https=)
CA2928969C (en) Compositions and methods for ophthalmic and/or other applications
US10292955B2 (en) Composition for external use preparation with improved transdermal permeability
JP2024057010A5 (https=)
MX2010003774A (es) Formulaciones oftalmicas acuosas.
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
JP2005537238A (ja) ポリヒドロキシアルカンの脂肪酸エステルおよびピリジンカルボキシ誘導体の新規複合体
JP2010502564A (ja) 眼科用経皮吸収型製剤
JP2016527306A (ja) 胆汁酸−脂肪酸抱合体を含む抗老化組成物
JP2021532145A (ja) 眼を治療するための組成物及び方法
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
CN103108640B (zh) 包含烟酸腺嘌呤二核苷酸磷酸或该烟酸腺嘌呤二核苷酸磷酸的衍生物的药学或者化妆料组合物
KR102006950B1 (ko) 양모ㆍ육모 촉진용 화장료 조성물
JP5646477B2 (ja) キトサンおよびジカルボン酸を含む、酒さ疾患を治療するための組成物
KR20210065968A (ko) 심미적 피부 상태를 치료하기 위한 철 킬레이팅 화합물
FR2518882A1 (fr) Composition therapeutique, a base de monophosphate d'inosine, pour le traitement des troubles d'accommodation de l'oeil
AU2007200216A1 (en) Skin formulation usable as a therapeutic application for the treatment of general skin disorders and a method of preparation thereof
JPH07233088A (ja) 局所外用剤
WO2016159351A1 (ja) 涙腺ドラッグデリバリーシステム
RU2802625C2 (ru) Композиции и способы лечения глаз
RU2806301C2 (ru) Композиции и способы лечения глаз
CN111246869A (zh) 含有香橙种子和糙米的提取物的组合物
JP2018002651A (ja) 慢性角化型湿疹改善剤